You are viewing: UK Hemostats Market analysis
Part of: Hemostats Market (Global)

The UK Hemostats Market was valued at $33.3 Million in 2025 and projected to reach to $46.9 Million by 2030, representing a compound annual growth rate of 7.1%. The UK hemostats market is positioned for sustained expansion through 2030, driven by increasing surgical procedures, rising trauma cases, and growing preference for advanced hemostatic technologies over traditional methods.

UK Hemostats Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Hemostats Market Trends and Insights

  • The UK market benefits from advanced healthcare infrastructure, high surgical volumes, and increasing adoption of advanced hemostatic agents in operating theaters and trauma centers.
  • The UK's regulatory environment and emphasis on patient safety drive demand for innovative hemostatic solutions across surgical specialties. In 2025, the UK hemostats market reflects strong demand from both public and private healthcare sectors, with the National Health Service (NHS) and private hospitals investing in modern hemostatic technologies.
  • By 2030, the UK market is anticipated to grow substantially as surgical procedures increase, aging populations require more interventions, and healthcare providers adopt next-generation hemostatic products.
  • The UK's position as a leader in medical device innovation supports market expansion through clinical adoption and reimbursement support. The UK hemostats market growth is underpinned by rising awareness of blood management protocols, increasing trauma and emergency surgical cases, and the integration of hemostatic agents into standard surgical practice.
  • The UK market is also influenced by European regulatory harmonization and cross-border medical device standards, positioning it as a key market within the broader European hemostats landscape..

Key Market Statistics

  • CAGR (2025-2030) 7.1% CAGR
  • Market Size, 2025 ~USD 33.3 Million
  • Forecast, 2030 ~USD 46.9 Million
  • Country UK

UK Hemostats Market Overview

Market Valuation :

The UK hemostats market is valued at $33.3 million in 2025 and is projected to reach $46.9 million by 2030, demonstrating robust growth potential in the region.

Strong Growth Trajectory :

With a CAGR of 7.1% from 2025 to 2030, the UK market outpaces the global average of 6.4%, reflecting accelerating adoption of advanced hemostatic solutions.

Advanced Healthcare Infrastructure :

The UK's well-established NHS and private healthcare systems, combined with high surgical volumes, create ideal conditions for hemostats adoption in operating theaters and trauma centers.

Regulatory Excellence :

The UK's stringent regulatory environment and patient safety focus drive demand for innovative, clinically-proven hemostatic agents that meet MHRA and NICE standards.

UK Hemostats Market Dynamics

  • Healthcare providers across the NHS and private sector are increasingly investing in next-generation products that improve patient outcomes and reduce operative time.
  • Regulatory support and clinical evidence backing modern hemostats further accelerate market penetration.
  • The market will benefit from aging demographics requiring more surgical interventions and enhanced focus on reducing blood loss complications in critical care settings..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • JOHNSON & JOHNSON

    Key Takeaways

    • The UK hemostats market is valued at $33.3 million in 2025 and is projected to reach $46.9 million by 2030, growing at a 7.1% CAGR.
    • The UK market is driven by advanced healthcare infrastructure, high surgical volumes, and strong adoption of innovative hemostatic agents in NHS and private hospitals.
    • Blood management protocols, trauma care expansion, and aging populations are key growth drivers for the UK hemostats market through 2030.
    • The UK's regulatory environment and position as a medical device innovation leader support sustained market expansion and clinical adoption of next-generation hemostatic solutions.

    Hemostats Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment RECONSTRUCTIVE SURGERY (Application)
    Forecast Period 2025–2030
    Growth Rate CAGR of 6.4% from 2025 to 2030
    Largest Segment HOSPITALS (End User)
    Market Size Base Year (Billions) ~USD 2.93 (2025)
    Revenue Forecast (Billions) ~USD 4 (2030)
    Segments Covered Type, Formulation, Application, End User

    UK Hemostats Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Collagen-Based Hemostats
    • Combination Hemostats
    • Gelatin-Based Hemostats
    • Other Types
    • Oxidized Regenerated Cellulose-Based Hemostats
    • Thrombin-Based Hemostats

    By Formulation

    • Matrix & Gel Hemostats
    • Powder Hemostats
    • Sheet & Pad Hemostats
    • Sponge Hemostats

    By Application

    • Cardiovascular Surgery
    • General Surgery
    • Gynecological Surgery
    • Neurological Surgery
    • Orthopedic Surgery
    • Other Surgeries
    • Reconstructive Surgery

    By End User

    • Hospitals
    • Specialty Clinics

    UK: HEMOSTATS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOSPITALS72.176.982.187.894.1100.9108.3116.57.2
    OTHERS11.712.112.613.113.714.31515.74.4
    SPECIALTY CLINICS23.524.826.227.629.33132.9356
    TOTAL107.3113.8120.9128.6137146.2156.2167.26.7

    Target Audience

    • Medical Device Manufacturers : Hemostats producers need UK market data to assess market entry opportunities, competitive landscape, and pricing strategies for NHS and private sector channels.
    • Healthcare Procurement Teams : NHS trusts and private hospital procurement departments require market insights to evaluate hemostats suppliers, negotiate contracts, and optimize surgical supply chains.
    • Clinical Decision-Makers : Surgeons, trauma specialists, and operating theater managers need evidence-based market data to select appropriate hemostatic products for their clinical protocols.
    • Investment & Private Equity Firms : Investors evaluating UK healthcare opportunities require detailed market sizing and growth forecasts to assess hemostats companies and portfolio expansion potential.
    • Healthcare Consultants & Analysts : Strategy consultants and market analysts need UK-specific hemostats data to support client advisory work, competitive analysis, and healthcare sector reports.

    Key Companies in the UK Hemostats Market

    CompanyHQOwnershipStrongest segments
    CSL LIMITEDUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    BAXTERUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    PFIZER INC.United StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    BECTON, DICKINSON AND COMPANY (BD)United States
    TELEFLEX INCORPORATEDUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    MEDTRONIC PLCIrelandPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    STRYKERUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    INTEGRA LIFESCIENCESUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    ADVANCED MEDICAL SOLUTIONS GROUP PLCUnited KingdomPublic CompanyGelatin-based hemostats,Collagen-based hemostats,Combination hemostats and biosurgical adjuncts,
    SAMYANG CORPORATIONKorea, Republic ofPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,

    CSL LIMITED

    CSL LIMITED is a public company founded in 1916 and headquartered in the United States, employing 29,904 people. The company operates in the biotechnology and pharmaceutical sectors.

    BAXTER

    BAXTER is a public company founded in 1931 in the United States, employing 37,500 people. The company operates in the medical devices and pharmaceutical sectors.

    PFIZER INC.

    PFIZER INC. is a public company founded in 1950 in the United States with 1,244 employees. The company operates in the pharmaceutical and healthcare industry.

    BECTON, DICKINSON AND COMPANY (BD)

    BECTON, DICKINSON AND COMPANY (BD) is a company headquartered in the United States. The company operates in the medical devices and healthcare sectors.

    TELEFLEX INCORPORATED

    TELEFLEX INCORPORATED is a public company founded in 1943 in the United States, employing 15,500 people. The company manufactures medical devices and specialty healthcare products.

    MEDTRONIC PLC

    MEDTRONIC PLC is a public company founded in 1949 and headquartered in Ireland, employing 95,000 people. The company is a global leader in medical technology and healthcare solutions.

    STRYKER

    STRYKER is a public company founded in 1941 in the United States, employing 56,000 people. The company is a leading manufacturer of medical devices and surgical equipment.

    INTEGRA LIFESCIENCES

    INTEGRA LIFESCIENCES is a public company founded in 1989 in the United States, employing 4,427 people. The company develops and manufactures medical devices and regenerative medicine products.

    ADVANCED MEDICAL SOLUTIONS GROUP PLC

    ADVANCED MEDICAL SOLUTIONS GROUP PLC is a public company founded in 1991 in the United Kingdom, employing 1,800 people. The company specializes in advanced wound care and medical device solutions.

    SAMYANG CORPORATION

    SAMYANG CORPORATION is a public company founded in 1961 in the Republic of Korea, employing 1,994 people. The company operates in the chemical and pharmaceutical manufacturing sectors.

    Reasons to Buy this Report

    • Market Size & Growth Data : Access precise UK market valuations ($33.3M in 2025) and forecasts through 2030, enabling accurate budget allocation and investment planning for hemostats portfolios.
    • Competitive Positioning : Understand UK-specific market dynamics, regulatory landscape, and adoption rates to benchmark your products against competitors and identify market gaps.
    • Strategic Expansion Planning : Leverage detailed UK market insights to develop targeted go-to-market strategies for NHS procurement, private hospitals, and trauma centers across the region.
    • Healthcare Provider Insights : Identify key decision-makers in UK operating theaters and trauma units, understand their procurement preferences, and align product offerings with clinical requirements.
    • Regulatory & Compliance Guidance : Navigate UK-specific MHRA approvals, NICE guidelines, and NHS standards with market intelligence tailored to the British healthcare regulatory framework.

    Frequently asked questions

    What is the current size of the UK hemostats market in 2025?

    The UK hemostats market is valued at $33.3 million in 2025, reflecting strong demand from both NHS and private healthcare providers.

    What is the projected size of the UK hemostats market by 2030?

    The UK hemostats market is forecast to reach $46.9 million by 2030, representing a 7.1% compound annual growth rate from 2025.

    What factors are driving growth in the UK hemostats market?

    Key growth drivers in the UK include advanced surgical infrastructure, increasing trauma cases, aging populations, blood management protocol adoption, and regulatory support for innovative hemostatic devices.

    How does the UK hemostats market compare to other European markets?

    The UK hemostats market, growing at 7.1% CAGR, is a significant segment within Europe, benefiting from strong healthcare infrastructure, high surgical volumes, and robust reimbursement frameworks.

    Which healthcare sectors are driving hemostats demand in the UK?

    The UK hemostats market is driven by demand from operating theaters, trauma centers, emergency departments, and surgical specialties within both NHS hospitals and private healthcare facilities.

    RESEARCH METHODOLOGY

    The study analyzes key market dynamics, such as drivers, opportunities, restraints, challenges, and key player strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, as well as the competitive landscape of the hemostats market, to analyze market players on various parameters within the broad categories of business and product strategy. Top-down approach was used to estimate the market size. The market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

    Secondary Research

    The secondary research process involved extensive use of various secondary sources, including directory databases like Bloomberg Business, Factiva, and D&B Hoovers, white papers, annual reports, company house documents, investor presentations, and SEC filings. This research was conducted to gather information valuable for a comprehensive, technical, market-oriented, and commercial study of the hemostats market. It also helped obtain critical insights about key players in the industry, market classification, and segmentation based on current industry trends down to the finest details. Additionally, a database of leading industry players was created through this secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.

    A breakdown of the primary respondents for the hemostats market is provided below:

    Hemostats Market

    Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.

    Note 2: Others include sales, marketing, and product managers.

    Note 3: Companies are classified into tiers based on their total revenue. As of 2024: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The research methodology used to estimate the size of the hemostats market includes the following details.

    The market sizing was undertaken from the global side.

    Top-down was used to estimate and validate the hemostats market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry have been identified through extensive secondary research
    • Primary and secondary research has determined the revenues generated by leading players operating in the hemostats market.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Hemostats Market Size: Top-down Approach

    Hemostats Market

    Data Triangulation

    After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    During surgical procedures, damage to blood vessels necessitates immediate intervention to mitigate hemorrhage—this process is referred to as hemostasis. Hemostatic agents work by facilitating the formation of fibrin clots, providing an interim solution to manage bleeding at the site. The application of hemostatic measures must be executed rapidly, precisely localized, and meticulously regulated, particularly in scenarios involving significant blood loss or in patients with congenital coagulopathies or trauma-induced vascular compromise.

    Stakeholders

    • Senior Management
    • Finance Department
    • Procurement Department
    • Hospitals
    • Specialty Clinics
    • Trade Associations and Industry Bodies
    • Regulatory Bodies and Government Agencies
    • Business Research & Consulting Service Providers
    • Market Research & Consulting Firms
    • Venture Capitalists and Investors

    Report Objectives

    • To define, describe, segment, analyze, and forecast the hemostats market by type, formulation, application, end user, and region
    • To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the hemostats market in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To profile the key players in the hemostats market and comprehensively analyze their core competencies
    • To track and analyze competitive developments such as agreements, collaborations, and partnerships; expansions; acquisitions; and product launches & approvals in the hemostats market

     

    Get the Full Hemostats Market Report

    Full forecast, segment splits, and company analysis for all Hemostats Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status